<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01092754</url>
  </required_header>
  <id_info>
    <org_study_id>1177-01-597</org_study_id>
    <nct_id>NCT01092754</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Optimark (Gadoversetamide) in Pediatric Patients</brief_title>
  <official_title>An Open-Label, Multicenter, Phase 4 Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Optimark(R) in Pediatric Patients (2-11 &amp; 12-18 Yrs) Referred for Contrast-Enhanced MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guerbet</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guerbet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to characterize the safety, efficacy and pharmacokinetic&#xD;
      profiles of Optimark at the standard clinical dose of 0.1 mmol/kg in the pediatric patient&#xD;
      population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pediatric patients referred for magnetic resonance imaging (MRI) of the liver or central&#xD;
      nervous system (CNS) will be stratified by age to one of two groups (2 through 11 and 12&#xD;
      through 18 years of age).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <completion_date type="Actual">December 2003</completion_date>
  <primary_completion_date type="Actual">December 2003</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess efficacy by analyzing the clinical diagnosis, degree of confidence in diagnosis and level of conspicuity of lesions.</measure>
    <time_frame>Immediately before and immediately after Optimark dosing</time_frame>
    <description>Optimark is an MRI contrast. Efficacy measurements will be determined from images obtained without contrast (immediately before) and with contrast (immediately after).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the safety of Optimark by analyzing adverse events and changes in vital signs, electrocardiograms (ECGs), physical exams, and clinical laboratory results.</measure>
    <time_frame>through 24 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the blood and urine PK levels of Optimark</measure>
    <time_frame>through 10 hours post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Pathological Processes</condition>
  <arm_group>
    <arm_group_label>A: Other</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B: Other</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>contrast enhanced MRI</description>
    <arm_group_label>A: Other</arm_group_label>
    <other_name>gadoversetamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>contrast enhanced MRI</description>
    <arm_group_label>B: Other</arm_group_label>
    <other_name>gadoversetamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gadoversetamide</intervention_name>
    <description>Subjects will receive a single dose of Optimark(0.1 mmol/kg)as a bolus thru a peripheral IV line at 1-2 mL/sec followed by a saline flush during their medically necessary MRI .</description>
    <arm_group_label>A: Other</arm_group_label>
    <arm_group_label>B: Other</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  2 thru 18 years of age&#xD;
&#xD;
          -  referred for MRI of the liver or CNS&#xD;
&#xD;
          -  if female and of child-bearing potential, must have negative pregnancy test within 24&#xD;
             hours of study drug administration&#xD;
&#xD;
          -  if applicable, agree to use medically accepted method of contraception throughout the&#xD;
             study&#xD;
&#xD;
          -  if necessary, patients entering the PK subgroup must be willing to be housed within&#xD;
             the investigational facility for a minimum of 24 hours following drug administration&#xD;
&#xD;
          -  understand the requirements of the study and provide written consent to participate,&#xD;
             agree to abide by the study requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  previously entered into this study or a previous study using Optimark&#xD;
&#xD;
          -  received investigational drug within 30 days of admission into this study or plan to&#xD;
             participate in a clinical study prior to the end of this study's monitoring period.&#xD;
             (patients on a research protocol using an approved drug ar acceptable)&#xD;
&#xD;
          -  medical condition, serious intercurrent illness, or extenuating circumstance that&#xD;
             would significantly decrease study compliance and all prescribed follow up&#xD;
&#xD;
          -  known or suspected abnormal renal function for age or requiring dialysis during the&#xD;
             study period&#xD;
&#xD;
          -  pregnant or breastfeeding&#xD;
&#xD;
          -  scheduled to undergo any contrast-enhanced examination within 7 days prior to baseline&#xD;
             examination or during the course of this study period&#xD;
&#xD;
          -  condition that is a contraindication to MRI (i.e., cardiac pacemaker, epicardial&#xD;
             pacemaker leads, cochlear implants, ferromagnetic aneurysm clip, ferromagnetic halo&#xD;
             device, or other condition that would preclude patient proximity to a strong external&#xD;
             magnetic field)&#xD;
&#xD;
          -  experienced a previous hypersensitivity reaction to a gadolinium-based contrast agent&#xD;
&#xD;
          -  recent history of hemolytic anemia, sickle cell anemia, or other hemoglobinopathy&#xD;
&#xD;
          -  undergone a surgical procedure within one week prior to study admission or are planned&#xD;
             to undergo a surgical procedure during study participation (central line placement is&#xD;
             acceptable)&#xD;
&#xD;
          -  history of significant claustrophobia&#xD;
&#xD;
          -  weighs less than 25 lbs (11 kgs)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eddie Darton, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mallinckrodt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arkansas Childrens Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital and Health Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Children's Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospitals and clinics</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State University Sciences Center- Shreveport</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardinal Glennon Childrens Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Childrens Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19092</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Childrens Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>March 15, 2010</study_first_submitted>
  <study_first_submitted_qc>March 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2010</study_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <name_title>Eddie Darton, Jr., M.D./Director, Global Drug Safety &amp; PVG</name_title>
    <organization>Mallinckrodt Inc.</organization>
  </responsible_party>
  <keyword>brain, spine, liver, MRI, Pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pathologic Processes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

